Based on the phenotypic features observed in the different assays described above, we hypothesize that JPX can promote cancer hallmarks by reducing the silencing activity of the miRNA toward its targets, competing with them for miRNA binding through the so-called ceRNA mechanism. The gene discussed is JPX; the disease is cancer.